Clinical trials
Localized Prostate Cancer clinical trials
Below are recruiting localized prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 483 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06780787RecruitingPhase 2
Study of chemo plus immunotherapy for localized rectal cancer before surgery
This trial tests a combination of chemotherapy (FOLFOX) and two immunotherapies (botensilimab and balstilimab) before surgery for patients with localized rectal cancer. It aims to see if adding immunotherapy helps shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT06922318RecruitingPhase 2
Combined suppression of MYC for advanced prostate cancer
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
Baltimore, MarylandAges 18 years+ - NCT07476001RecruitingPhase 2
High-dose testosterone and PSMA-targeted radiation for prostate cancer
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
Tampa, FloridaAges 18 years+ - NCT05956639RecruitingPhase 3
Rezvilutamide with ADT and chemo: shorter versus longer treatment
This Phase 3 trial compares two lengths of rezvilutamide treatment when given with hormone therapy (ADT) and chemotherapy for men with advanced prostate cancer. It aims to find which treatment duration works best and is safest to help control the cancer.
Nanjing, JiangsuAges 18 years+ - NCT06136624RecruitingPhase 3
Comparing a new drug to standard hormone therapy for advanced prostate cancer
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
Orange, CaliforniaAges 18 years+ - NCT07142967Recruiting
MR-Linac radiotherapy for prostate cancer that returned after earlier radiation
This trial tests if a special MRI-guided radiotherapy machine (MR-Linac) can safely treat prostate cancer that has come back after previous radiation therapy. It may help men who have limited options and want to avoid more invasive treatments.
New York, New YorkAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07093866RecruitingPhase 2
Targeted drug combo for advanced prostate cancer
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
Nanjing, JiangsuAges 18–75 - NCT07259213RecruitingPhase 1/Phase 2
Study of a new drug (161Tb-RAD402) for men with advanced prostate cancer
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Wollongong, New South WalesAges 18 years+ - NCT07162779Enrolling by invitation
New PET scan for advanced prostate cancer patients
This trial tests a new type of PET scan using a radioactive tracer called [68Ga]DOTA-IR-780-C-4 to see if it can find prostate cancer cells that express a protein called PSMA. If you have advanced prostate cancer that has stopped responding to standard treatments, this scan may help your doctor better understand your cancer and possibly guide future care.
Wuxi, JiangsuAges 18–80 - NCT05939414RecruitingPhase 3
Lutetium prostate cancer treatment for limited PSMA-spread
This Phase 3 trial compares a targeted radiation medicine called lutetium (177Lu) vipivotide tetraxetan versus watchful waiting in people with prostate cancer that has spread to only a few spots. The goal is to see if the treatment can better control the cancer when scans show a small amount of PSMA-positive metastases.
Fayetteville, ArkansasAges 18–100 - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT05354375RecruitingPhase 1
PSMA-targeted CAR-T cell therapy for resistant prostate cancer
This Phase 1 study tests whether lab-made immune cells (CAR-T) that target PSMA can treat prostate cancer that keeps growing despite hormone treatment. It may help people whose disease no longer responds to standard endocrine (hormone-blocking) therapy.
Xuzhou, JiangsuAges 18–75 - NCT07747272Recruiting
Nerve-sparing prostate surgery and erectile function
This study looks at how your health before surgery affects your erectile function after robot-assisted prostate removal. It aims to help doctors predict and improve recovery of erectile function.
Florence, ItalyAges 18–75 - NCT07006727RecruitingPhase 1
Targeted radiation therapy for DLL3-positive advanced cancers
This study tests a new targeted radiation therapy (called [225Ac]Ac-ETN029) for people with advanced cancers that have a protein called DLL3 on their cells. The treatment is designed to deliver radiation directly to cancer cells, and the goal is to see if it is safe and effective.
Iowa City, IowaAges 18–100 - NCT06981026Recruiting
Checking if remote health coaching helps before prostate surgery
This study tests whether using a smartphone or computer to get health coaching before prostate cancer surgery helps people recover faster and have better results. You will be asked to exercise and track your health at home while staying connected with your care team.
OlomoucAges 40–80 - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Homewood, AlabamaAges 18–100 - NCT07707232Recruiting
Using AI to read PSMA PET/CT reports for prostate cancer
This trial uses a computer program (large language model) to help doctors read Chinese PSMA PET/CT reports. The goal is to see if the AI can accurately identify key details about prostate cancer, like where it has spread, which may help make staging and treatment decisions faster.
Wenzhou, ZhejiangAges 18 years+ - NCT06520345RecruitingPhase 3
A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Orange, CaliforniaAges 18 years+ - NCT03067051RecruitingPhase 1/Phase 2
Test of a prostate cancer light-activated treatment device
This study tests the safety and early effectiveness of the SpectraCure P18 system, which uses light-activated medicine to treat prostate cancer that has come back locally after radiation. It may help some people avoid or delay more invasive treatment, while researchers carefully watch side effects.
New York, New YorkAges 18 years+ - NCT05435495Recruiting
Study why PSMA radioligand therapy stops working
This study looks at tissue samples from tumors to understand how and why PSMA radioligand therapy may become less effective. If you have PSMA-avid cancer lesions that can be biopsied, the trial may help researchers find ways to improve treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05558007RecruitingPhase 2
Topical treatment trial after prostate surgery in men
This Phase 2 study tests how safe and effective a topical medicine (BZ371A) is for men after prostate surgery, with the goal of improving sexual recovery and monitoring side effects. You may be able to join if you meet specific timing, health, and medication criteria after radical prostatectomy.
Belo HorizonteAges 40–65 - NCT05710861Recruiting
Focal HIFU versus prostate surgery: cost and quality of life
This trial compares focal HIFU (a targeted heating treatment inside the prostate) with prostate surgery, looking at overall cost and quality of life. It may help people with certain early, limited prostate cancers understand which option fits best for them.
BesançonAges 50–75 - NCT05722392Recruiting
Two-step surgery for localized prostate cancer
This trial studies a “two-step” type of prostate removal surgery for men with localized prostate cancer, focusing on whether it is safe and effective. It may help if you have certain prostate size, PSA level, and tumor features that match their criteria.
Guangzhou, GuangdongAges Any age
Hear when a new Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for localized prostate cancer?
- Yes. Clin2 currently lists 483 recruiting localized prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a localized prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a localized prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.